A breast cancer drug with a known risk to the retina has no formal screening guideline, and real-world eye clinic records ...
Hospitals may need to revise staffing arrangements, designate exposure-free areas, and establish procedures for removing and ...
A newly diagnosed autoimmune disease may complicate the evaluation of profound thrombocytopenia, while this case highlights ...
A 68-year-old man develops thoracic pain and recurrent fever 11 years after laparoscopic cholecystectomy; imaging reveals a perihepatic abscess linked to a gallstone.
New data from California wildfire zones suggest link between in utero exposure to pollutants and asthma in early childhood.
Pharmacists weigh clinical benefits, safety, trial relevance, and cost when deciding whether a cancer drug merits public funding.
Patient characteristics at baseline and weight loss in the first 3 months on a GLP-1 drug were tied to weight-loss outcomes ...
Avexitide, a GLP-1 receptor antagonist, could become the first approved treatment for the debilitating condition.
When two experts were asked to discuss JAK inhibitors relative to biologics in the management of moderate-to-severe atopic dermatitis, they agreed each choice has a clinical context.
After a GLP-1, what works next? Among more than 20,000 patients, surgery was linked to the most weight loss, quitting cold the least, and switching from semaglutide to tirzepatide beat staying put.
Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.
Adding online support to tirzepatide was projected to lead to greater health gains than the drug alone, assuming no extra cost, in a UK model of adults with obesity.